Abstract Number: 1368 • ACR Convergence 2022
How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey
Background/Purpose: Pediatric scleroderma consists of two diseases, juvenile localized scleroderma (jLS) and juvenile systemic sclerosis (jSSc). While jLS and jSSc share some disease processes, there…Abstract Number: 1382 • ACR Convergence 2022
Juvenile Eosinophilic Fasciitis: A Single-Center Cohort
Background/Purpose: Eosinophilic fasciitis (EF) is a rare fibrosing disease. Since described in 1975, less than 30 pediatric cases have been reported. EF presents with painful…Abstract Number: 1518 • ACR Convergence 2022
Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study
Background/Purpose: Digital ischemic complications (DICs, including digital ulcers, digital pitting/scars, gangrene and/or amputation) can significantly impact hand function, disability and overall prognosis in SSc. We…Abstract Number: 1542 • ACR Convergence 2022
Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry
Background/Purpose: Classification of systemic sclerosis (SSc) into subsets has been a challenge due to it's heterogeneity. This study attempts to identify SSc subsets based on…Abstract Number: 1946 • ACR Convergence 2022
Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile
Background/Purpose: Commercially available autoantibody (AAb) panels are developed for adult rheumatological diseases; application to pediatric disease has not been established. As a pediatric scleroderma referral…Abstract Number: 0781 • ACR Convergence 2021
Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare chronic inflammatory and fibrosing disease associated with a high risk for morbidity in children. Methotrexate (MTX) has…Abstract Number: 0979 • ACR Convergence 2021
Autoantibody Testing in Juvenile Localized Scleroderma and Systemic Sclerosis: Comparing Antibody Profiles and Clinical Correlations
Background/Purpose: Pediatric scleroderma encompasses juvenile onset localized scleroderma (jLS) and juvenile onset systemic sclerosis (jSSc), both of which present with varied cutaneous fibrosis and systemic…Abstract Number: 1856 • ACR Convergence 2021
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…Abstract Number: 0772 • ACR Convergence 2021
Pediatric Craniofacial Scleroderma: Assessing Handheld 3D Stereophotogrammetric Imaging Feasibility and Reliability
Background/Purpose: Craniofacial scleroderma (Cf-LS), also known as Parry-Romberg Syndrome or scleroderma en coup de sabre, is a subtype of localized scleroderma (morphea). Diagnosis and monitoring…Abstract Number: 0175 • ACR Convergence 2020
Identifying Immuno-phenotypes in Juvenile Localized Scleroderma with RNA Sequencing
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease of the skin and underlying tissue characterized by an early inflammatory infiltrate followed by fibrosis and…Abstract Number: 0394 • ACR Convergence 2020
Prevalence of a Diagnosis of Osteopenia/Osteoporosis Amongst Patients with Systemic Sclerosis and Identification of Associated Clinical Factors
Background/Purpose: This study aims to determine the prevalence of a diagnosis of osteopenia/osteoporosis (OP) in systemic sclerosis (SSc) patients and to identify the clinical and…Abstract Number: 0916 • ACR Convergence 2020
Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis
Background/Purpose: Patients with systemic sclerosis (SSc) frequently experience gastrointestinal (GI) symptoms, ranging from mild to debilitating in severity. Better prediction of those most at risk…Abstract Number: 1035 • ACR Convergence 2020
Study of Ocular Sarcoidosis and Clusters of Clinical Associations in a Series of 383 Patients with Systemic Sarcoidosis from a Single Hospital
Background/Purpose: Sarcoidosis is an inflammatory disease which can affect multiple organs. The most frequent affected organs are lungs, skin and eyes. Ocular involvement is a…Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…Abstract Number: 1560 • ACR Convergence 2020
Measuring Asymmetry in Facial Morphea via 3D Stereophotogrammetry
Background/Purpose: Morphea is an autoimmune disorder causing sclerosis and inflammation of the skin and subcutaneous tissue. Facial morphea can cause substantial disfigurement and negative impact on quality of life. Existing clinical measures such…
ACR Meeting Abstracts